Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, Jonas O, Gray JW, Korkola JE.

Cell Syst. 2018 Mar 28;6(3):329-342.e6. doi: 10.1016/j.cels.2018.02.001. Epub 2018 Mar 14.

2.

Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.

Hassan S, Esch A, Liby T, Gray JW, Heiser LM.

Mol Cancer Ther. 2017 Dec;16(12):2892-2901. doi: 10.1158/1535-7163.MCT-17-0170. Epub 2017 Sep 27.

PMID:
28958991
3.

Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells.

Liby TA, Spyropoulos P, Buff Lindner H, Eldridge J, Beeson C, Hsu T, Muise-Helmericks RC.

Int J Cancer. 2012 Feb 1;130(3):532-43. doi: 10.1002/ijc.26010. Epub 2011 Apr 20.

4.

VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase.

Wright GL, Maroulakou IG, Eldridge J, Liby TL, Sridharan V, Tsichlis PN, Muise-Helmericks RC.

FASEB J. 2008 Sep;22(9):3264-75. doi: 10.1096/fj.08-106468. Epub 2008 Jun 4.

Supplemental Content

Support Center